免疫调节使晚孕期移植小鼠模型实现耐受与植入
本研究以小鼠20天胎龄(DPC)移植模拟人类晚孕期移植,探讨抗CD3单克隆抗体免疫调节能否实现供者特异性耐受和持续异基因植入,并与14 DPC早期胎儿受者比较。结果显示抗CD3单抗联合移植导致短暂T细胞清除,随后通过供者特异性克隆删除和皮肤移植物耐受证实中枢耐受诱导,且对第三方主要组织相容性复合体和病毒病原体的正常免疫应答得以保留,未发生移植物抗宿主病。该方法在镰状细胞病Townes小鼠模型中也成功应用。
要点
- 抗CD3单抗联合移植在晚孕期小鼠模型中诱导短暂T细胞清除和中枢耐受。
- 供者特异性克隆删除和皮肤移植物耐受证实耐受诱导,第三方免疫和病毒应答保留。
- 该方法在镰状细胞病Townes小鼠模型中成功应用,支持短暂T细胞清除作为安全有效的免疫调节策略。
核心结论
- 这些发现证实发育中的胎儿T细胞反应是晚孕期移植的屏障,并支持短暂T细胞清除作为安全有效的免疫调节策略来克服该屏障。
研究设计与样本
- 使用小鼠20天胎龄(DPC)新生儿移植作为人类晚孕期移植(LGT)模型,并与14 DPC早期胎儿受者比较。
- 在异基因野生型品系组合中,移植时给予抗CD3单克隆抗体(mAb),观察免疫耐受和植入情况。
- 进一步在镰状细胞病(SCD)Townes小鼠模型中应用该方法。
主要发现
- 在异基因野生型品系组合中,抗CD3 mAb联合移植导致短暂T细胞清除,随后通过供者特异性克隆删除和皮肤移植物耐受证实中枢耐受诱导。
- 对第三方主要组织相容性复合体和病毒病原体的正常免疫应答得以保留,且未发生移植物抗宿主病。
- 在镰状细胞病Townes小鼠模型中成功应用该方法。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In utero hematopoietic cell transplantation is an experimental nonmyeloablative therapy with potential applications in hematologic disorders, including sickle cell disease (SCD). Its clinical utility has been limited due to the early acquisition of T-cell immunity beginning at ∼14 weeks gestation, posing significant technical challenges and excluding treatment fetuses evaluated after the first trimester. Using murine neonatal transplantation at 20 days postcoitum (DPC) as a model for late-gestation transplantation (LGT) in humans, we investigated whether immune modulation with anti-CD3 monoclonal antibody (mAb) could achieve donor-specific tolerance and sustained allogeneic engraftment comparable with that of the early-gestation fetal recipient at 14 DPC. In allogeneic wild-type strain combinations, administration of anti-CD3 mAb with transplantation resulted in transient T-cell depletion followed by central tolerance induction confirmed by donor-specific clonal deletion and skin graft tolerance. Normal immune responses to third-party major histocompatibility complex and viral pathogens were preserved, and graft-versus-host disease did not occur. We further demonstrated the successful application of this approach in the Townes mouse model of SCD. These findings confirm the developing fetal T-cell response as a barrier to LGT and support transient T-cell depletion as a safe and effective immunomodulatory strategy to overcome it.
引用
- Riley JS, Berkowitz CL, Luks VL, et al. Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation. Blood Adv. 2024. PMID: 38941538. doi:10.1182/bloodadvances.2023012247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。